Market Overview

Revance Therapeutics Regains All Worldwide Rights to Its Botulinum Toxin Products; Will Make Upfront Payment of $7M, Up to Added $18M Payments; Medicis Will Keep Equity Stake in Revance

Related MRX
Valeant Pharmaceuticals And Galderma Agree On Revised Agreement Terms
Medicis Pharmaceutical Spikes Higher on 8-K Filing Regarding Dismissed Lawsuit

Revance Therapeutics, Inc. (Revance) today announced a settlement and termination agreement for its contractual relationships with Medicis Pharmaceutical Corporation (NYSE: MRX) concerning RT001 Botulinum Toxin Type A Topical Gel and RT002 Injectable Botulinum Toxin Type A. As part of the settlement, all worldwide rights to develop and commercialize both products across all indications will be returned to Revance. The agreement will also resolve the outstanding litigation between the companies.

Posted-In: News FDA Legal

 

Related Articles (MRX)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters